DarioHealth Signs NBA Legend Dominique Wilkins as Brand Ambassador
Partnership to Increase Awareness of MyDario and Drive Growth of New Customers
CAESAREA, Israel and ATLANTA, April 19, 2017 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced a brand ambassador partnership with NBA great and Naismith Memorial Basketball Hall of Famer Dominique Wilkins. The focus of the partnership is to advance awareness of MyDario, drive growth of new customers and increase market penetration. The multi-year agreement encompasses collaboration on social media, digital marketing and public appearances.
A year after his retirement as a legendary professional basketball player, Wilkins received devastating news about his health: he was a type 2 diabetic. With his striking physical presence on the court and good health during his 16-year professional career, the discovery left Wilkins in denial. Although his grandfather and father had both died from diabetes, he never worried or tried to thwart off the disease because he was in great shape from basketball.
"Diabetes is a complex disease and I am always striving to stay ahead with the latest innovations to help me monitor and beat it," said Wilkins. "A few months ago, I started using MyDario on a daily basis to monitor my blood glucose levels. I found the MyDario plug-in enabling my smartphone to become a glucose meter device to be extremely easy to set up and use. I really like the compact design and convenience of making what I already carry with me all day, my smartphone, into a medical device. The MyDario mobile app is strong in its ability to manage and analyze the data inputs, leading to the management of a healthier lifestyle. I am excited to partner with DarioHealth to help others be more proactive and to think differently about managing their diabetes."
Erez Raphael, Chief Executive Officer of DarioHealth, stated, "We are excited about MyDario partnering with such a beloved and recognizable talent. Dominique Wilkins is passionate about his fight and efforts in dealing with diabetes and will undoubtedly maximize the MyDario brand potential and be a powerful agent for change. We are honored that Dominique has chosen DarioHealth to help him in his daily battle with diabetes and believe he will inspire others to live a healthier life."
Please be sure to follow DarioHealth, MyDario and Dominique Wilkins: http://www.dominiquewilkins21.com
About Dominque Wilkins
Dominique Wilkins is a legendary professional basketball player who began his career playing for the Atlanta Hawks. Wilkins was a nine-time NBA All-Star, and one of the all-time elite scoring machines in NBA history, living up to his college nickname "The Human Highlight Film." In 2006, Wilkins' career was immortalized and celebrated with his induction into the Naismith Memorial Basketball Hall of Fame. Wilkins currently serves as the Hawks' Vice President of Basketball Operations, where he transfers his basketball passion and knowledge to the next generation of elite NBA athletes.
About DarioHealth Corp.
DarioHealth Corp. is a leading global digital health company serving tens of thousands of users with dynamic mobile health solutions. We believe people deserve the best tools to manage their treatment, and harnessing big data, we have developed a unique way for our users to analyze and personalize their diabetes management. With our smart diabetes solution, users have direct access to track and monitor all facets of diabetes, without having the disease slow them down. The acclaimed Dario™ Blood Glucose Monitoring System all-in-one blood glucose meter and native smartphone app gives users an unrivaled method for self-diabetes management. DarioHealth is headquartered in Caesarea, Israel with a regional office in Burlington, Massachusetts. For more information, visit http://mydario.investorroom.com/.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. For example, when the Company states that the focus of the partnership with Dominique Wilkins is to drive growth of new customers and increase market penetration, and that the partnership will maximize the MyDario brand potential, it is using forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
DarioHealth Corporate and Media Contact
DarioHealth Investor Relations Contact
Rob Fink / Brett Maas
646-415-8972 / 646-536-7331
SOURCE DarioHealth Corp.
More by this Source
DarioHealth Expands Global Presence With Direct-to-Consumer Launch in the U.K.
26 Apr, 2017, 15:00 IDT
DarioHealth Corp. Completes $4.5 Million Public Offering of Common Stock
05 Apr, 2017, 23:05 IDT
DarioHealth Corp. Prices Offering of 1,450,000 Shares of Common Stock
31 Mar, 2017, 15:00 IDT
Get content for your website
Enhance your website's or blog's content with PR Newswire's customised real-time news feeds.